Literature DB >> 16301389

Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers.

Alexander J Stratigos1, Dimitrios Malanos, Giota Touloumi, Anna Antoniou, Irene Potouridou, Dorothea Polydorou, Andreas D Katsambas, Denise Whitby, Nancy Mueller, John D Stratigos, Angelos Hatzakis.   

Abstract

OBJECTIVE: To evaluate various immunologic markers in the peripheral blood of patients with early and advanced classic Kaposi's sarcoma (CKS).
DESIGN: Cross-sectional study.
SETTING: A major referral center for skin and venereal diseases. PATIENTS: Sixty-eight patients with histologically confirmed CKS staged according to a modified version of the Mitsuyasu-Groopman classification in stage I-II (cutaneous involvement only) and stage IV (skin and systemic involvement). MAIN OUTCOME MEASURES: Concentrations of neopterin and beta2-microglobulin, titer of anti-human herpesvirus 8 antibodies, number of natural killer cells, and numbers of total lymphocytes, B lymphocytes, T lymphocytes, and their subsets in peripheral blood.
RESULTS: The median values of beta2-microglobulin and neopterin were elevated in patients with CKS in stage IV (median, 3.679 microg/mL [312.72 nmol/L] and 14.0 nmol/L, respectively) compared with patients in stage I-II (median, 2.406 microg/mL [204.51 nmol/L] and 6.5 nmol/L, respectively). A statistically significant reduction in total lymphocyte and B-lymphocyte counts was observed in patients with advanced-stage CKS (1679/microL and 79/microL, respectively) compared with patients in earlier stages of the disease (2142/microL and 224/microL, respectively). The human herpesvirus 8 antibody titer, determined by latent immunofluorescent assay, decreased from stage I-II to stage IV, although not at a statistically significant level (P = .14).
CONCLUSION: The evolution of CKS from the early stages of the disease to the more advanced may be associated with a partial activation of the immune system and a gradual decrease in the number of total and B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301389     DOI: 10.1001/archderm.141.11.1421

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

2.  CD4+ and CD8+ T-cell skewness in classic Kaposi sarcoma.

Authors:  Antonio Galleu; Claudio Fozza; Maria Pina Simula; Salvatore Contini; Patrizia Virdis; Giovanna Corda; Simonetta Pardini; Francesca Cottoni; Sara Pruneddu; Antonio Angeloni; Simona Ceccarelli; Maurizio Longinotti
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

3.  Kaposi Sarcoma in a Non HIV Patient.

Authors:  Rafi A Jan; Parvaiz A Koul; Manzoor Ahmed; Sonaullah Shah; Showkat A Mufti; Fayaz A War
Journal:  Int J Health Sci (Qassim)       Date:  2008-07

4.  Pathology of rituximab-induced Kaposi sarcoma flare.

Authors:  Liron Pantanowitz; Klaus Früh; Sharon Marconi; Ashlee V Moses; Bruce J Dezube
Journal:  BMC Clin Pathol       Date:  2008-07-23

5.  Chronic cough conundrum: a case report of a new diagnosis of HIV and pulmonary Kaposi's sarcoma.

Authors:  Pamela P Bailey; Marylou M Dryer; John P Piper; Sajjad Ahmad
Journal:  BMC Pulm Med       Date:  2017-03-20       Impact factor: 3.317

Review 6.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

7.  Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation.

Authors:  Louise E Hogan; Emily Hanhauser; Kristen S Hobbs; Christine D Palmer; Yvonne Robles; Stephanie Jost; Anne S LaCasce; Jeremy Abramson; Ayad Hamdan; Francisco M Marty; Daniel R Kuritzkes; Timothy J Henrich
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.